title: Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study).
abstract: OBJECTIVE
  The ACTION (Assessment of Cost and ouTcomes of chemotherapy In an Observational setting) study investigated associations between chemotherapy, patient/disease characteristics and outcomes in advanced non-small cell lung cancer (NSCLC) patients in clinical practice.
  
  
  METHODS
  Chemonaïve NSCLC patients from five European countries were observed for 18 months from initiation of first-line chemotherapy; care was at the physician's discretion.
  
  
  METHODS
  Survival and associated prognostic factors were estimated using Kaplan-Meier methods and a Cox proportional hazards model, respectively. Cluster analyses of baseline patient characteristics were also performed. Toxicity data were not considered in these analyses.
  
  
  RESULTS
  A total of 975 eligible patients with NSCLC (Stage IIIb/IV) were enrolled and provided baseline and response data; cluster analysis was performed on 829 patients and survival data were available from 906 patients. In first-line treatment, a 39.8% response rate, a 39.5% 1-year survival rate and unadjusted median survival of 9.3 months were observed. Prognostic factors for survival included performance status (PS), number of metastatic organs, gender and age. Five patient clusters were identified, highlighting patient heterogeneity in terms of baseline condition and age. PS was maintained or improved throughout first-line and second-line chemotherapy in half the patients receiving these treatments.
  
  
  CONCLUSIONS
  ACTION provides valuable information about patient population, disease characteristics, treatment choices, prescribing patterns and outcomes in routine clinical practice in advanced NSCLC in Europe. Our findings suggest that maintenance of PS after first and subsequent lines of chemotherapy, and survival rates may both be higher than previously anticipated. Our results also showed an association between age and survival, which suggests that age should not exclude patients from receiving chemotherapy if they meet all other eligibility criteria.
authors.affiliation: Thoraxklinik, Heidelberg, Germany. Helge.Bischoff@thoraxklinik-heidelberg.de
authors.forename: Helge G
authors.initials: HG
authors.lastname: Bischoff
authors.forename: Ben
authors.initials: B
authors.lastname: van den Borne
authors.forename: Francisco L
authors.initials: FL
authors.lastname: Pimentel
authors.forename: Jorge
authors.initials: J
authors.lastname: Arellano
authors.forename: Frank
authors.initials: F
authors.lastname: Langer
authors.forename: Monika I
authors.initials: MI
authors.lastname: Leschinger
authors.forename: Nicholas
authors.initials: N
authors.lastname: Thatcher
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D016000:Cluster Analysis; D005060:Europe; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019370:Observation; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents